Post-Traumatic Stress Disorder

Our most important partnership? Our patients.

SpringWorks Therapeutics is working with patients, families and advocacy groups to understand the patient experience—what it’s like for patients living day-to-day with a disease. Our mission is to translate these learnings into tangible solutions for patients, such as improving the design of our clinical trials.

Post-Traumatic Stress Disorder

Post-traumatic stress disorder (PTSD) is a chronic condition that some people develop after experiencing traumatic or life-threatening events, serious injury, or sexual violence. PTSD involves the persistent re-experiencing of the traumatic event and is often seen in military veterans, first responders, rape and battery victims, and abused children.

Our Therapy

  • Name: PF-04457845, a fatty acid amide hydrolase (FAAH) inhibitor
  • Demonstrated good safety/tolerability profile in previous Phase 1 studies

How It Works

FAAH (fatty acid amide hydrolase) is an integral membrane enzyme that hydrolyzes the fatty amide family of lipid transmitters including endocannabinoid, an important neurotransmitter in the brain. By inhibiting FAAH, our therapy may potentially increase the concentration of endocannabinoids, which is implicated in a wide range of physiological processes including depression and anxiety disorders.

Key Papers

  • TBD

Program Status: Phase 2 Ready

SpringWorks is planning to conduct a Phase 2 study in patients to better understand the utility of our FAAH compound for treatment of PTSD.